

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. 1057-04		SERIAL NO. 10/803,366	
LIST OF PRIOR ART CITED BY APPLICANT <small>(Use several sheets if necessary)</small>				APPLICANT: Frédéric Triebel			
				FILING DATE: Herewith		GROUP 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS								
PV	AK	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AK	WO 97/03695	02/06/97	PCT	/	/	x	
	AL	EP 0 893 507 A1	01/27/99	Europe			x	
	AM	EP 0 900 841 A1	03/10/99	Europe			x	
	AN							
	AO							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
PV	Terry W. Pearson et al., <u>PROCYCLIN: AN IMMUNODOMINANT TRYPANOSOME SURFACE ANTIGEN WITH POTENTIAL FOR USE AS A TRANSMISSION BLOCKING VACCINE</u> , UCLA Symposia on Molecular and Cellular Biology, New York, NY, US, Vol. 84, 01/30/88, pages 45 – 56
PV	S. Gaisser et al., <u>The <i>tonB</i> gene of <i>Serratia marcescens</i>: sequence, activity and partial complementation of <i>Escherichia coli tonB</i> mutants</u> , Molecular Microbiology (1991), 5(11), pages 2777- 2787
PV	Hiromi Fukamachi et al., <u>Identification of a Protein, SPY75, with Repetitive Helix-Turn-Helix Motifs and an SH3 Domain as a Major Substrate for Protein Tyrosine Kinase(s) Activated by FccRI Cross-Linking</u> , Journal of Immunology, Vol. 152, No. 2, 1994, pages 642 – 652
PV	Bertrand Huard et al., <u>T cell major histocompatibility complex class II molecules down-regulate CD4⁺ T cell clone responses following LAG-3 binding</u> , European Journal of Immunology, Weinheim, DE, Vol. 26, 05/01/96, pages 1180 – 1186
PV	Bertrand Huard et al., <u>Characterization of the major histocompatibility complex class II binding site on LAG-3 protein</u> , Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, US, Vol. 94, No. 11, 05/01/97, pages 5744 – 5749
PV	Aram Mangasarian et al., <u>Nef-Induced CD4 and Major Histocompatibility Complex Class I (MHC-I) Down-Regulation Are Governed by Distinct Determinants: N-Terminal Alpha Helix and Proline Repeat of Nef Selectively Regulate MHC-I Trafficking</u> , Journal of Virology, Vol. 73, No. 3, 03/99, pages 1964 – 1973

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1057-04

SERIAL NO.

APPLICANT: Frédéric Triebel

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

FILING DATE: Herewith

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AK							
	AL							
	AM							
	AN							
	AO							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PV		Sigrid Hannier et al., <u>The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes</u> , International Immunology, Vol. 11, No. 11, 11/99, pages 1745 – 1752
PV	AP	Gaëlle Ferrières et al., <u>Affinity for the cognate monoclonal antibody of synthetic peptides derived from selection by phage display</u> , European Journal of Biochemistry, Berlin, DE, Vol. 6, No. 267, 03/2000, pages 1819 – 1829
PV	AQ	Nathalie Iouzalet et al., <u>LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway</u> , European Journal of Immunology, 31(10), 10/01, pages 2885 – 2891
	AR	

EXAMINER /F Pierre Vandervegt/

DATE CONSIDERED 03/05/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.